CymaBay Therapeutics has scrapped two mid-stage trials of seladelpar in non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC), ending development of its lead drug. Shares in ...

Update after two years: It has been a long time since I have created this repository to guide people who are getting started with pytorch (like myself back then). However, over the course of years and ...